Ketamine metabolite relieves depression with fewer side effects
Study findings could inform the development of more effective and safe treatments for depression.
Source: M. I. Walker / Science Photo Library
Ketamine has shown promise as a rapid-onset treatment for severe depression, but its mechanism of action is unclear.
Reporting in Nature (online, 4 May 2016), researchers studied the effect of ketamine metabolites in mice. They found that blocking formation of one particular metabolite – (2S,6S;2R,6R) hydroxynorketamine – prevented the antidepressant effect of ketamine.
The team then showed that the metabolite can induce antidepressant effects similar to ketamine but without the related side effects. This action was not via inhibition of N-methyl-d-aspartate receptors (NMDAR), as ketamine has previously been thought to work, but via α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs), another type of glutamate receptor in the brain.
The researchers say that the findings are relevant to the development of more effective and safe treatments for depression.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201158
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now